Checkpoint Therapeutics (CKPT) announced that the U.S. FDA has approved unloxcyt for the treatment of adults with metastatic cutaneous squamous ...

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

The major types of skin cancer are basal cell carcinoma, squamous cell carcinoma, and melanoma. Basal cell carcinoma is the ...

Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved UNLOXCYT ...

Shares of Checkpoint Therapeutics rose 4.6% to $3.84 in post-market trading after the Food and Drug Administration approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma, ...

Checkpoint Therapeutics said the Food and Drug Administration approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma, the company's first approval. Checkpoint said in July ...

L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- . (“Checkpoint”) ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted ...

BioNTech (BNTX) said it has been informed by its partner OncoC4 that the Food and Drug Administration has lifted the partial clinical hold on ...

The company also has other arrows in its quiver. It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced ...

Volrustomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Malignant Pleural Mesothelioma.